Forte Biosciences is, for the moment, a deal rather than a development story. On July 26, 2026 the company signed a definitive agreement to be acquired by argenx at $77.00 per share in cash, and as of last week the stock has been trading within a basis point of that price. With approximately 21.2 million shares outstanding, the announced equity value is roughly $1.63 billion, or about $1.44 billion after backing out $198.5 million of cash and short-term investments on the June 30, 2026 balance sheet. There is no financing condition on the offer, the minimum tender threshold is a narrow majority of outstanding shares, and the merger would follow under Section 251(h) of Delaware law without a stockholder vote. Holders who bought before the deal was announced have captured a meaningful premium (around 56% versus the 10-day volume-weighted average price of $49.33), but new money comes in at a deal-arb spread of roughly two basis points and is therefore underwriting regulatory timing and deal certainty, not the underlying science.
The underlying science nonetheless matters for downside. Forte is a single-asset clinical-stage biopharmaceutical company whose entire investment thesis rests on FB102, an anti-CD122 monoclonal antibody now in two Phase 1b trials and a Phase 2 celiac study. Positive Phase 1b readouts in celiac disease (June 2025) and vitiligo (July 2026) drove the stock from a 52-week low of $10.11 to the high-$50s ahead of the deal. The argenx transaction is, in effect, a takeout of that science story at a moment of maximum excitement. If the deal breaks, the equity will reprice to a Phase 2 readout cadence with significant clinical risk and a $198.5 million cash buffer that the company says funds at least twelve months of operations.
The central questions for the next three to six months are mechanical: tender acceptance levels, Hart-Scott-Rodino antitrust clearance, and the absence of a topping bid. The current trading spread suggests the market assigns a high probability to all three. Net cash on the balance sheet plus an undrawn S-3 shelf for up to $500 million in securities provide a meaningful backstop even in a deal-break scenario, and the absence of a competing public offer through the first four weeks of the tender period suggests that the strategic-buyer set for FB102 outside of argenx is narrow. The right way to read FBRX today is as a near-certain deal-arb position with a small option on the underlying science, not as a development-stage biotech whose value depends on Phase 2 data.